Glenmark Pharmaceuticals receives ANDA approval for Potassium Chloride Extended-Release Capsules

21 Jan 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Potassium Chloride Extended-Release Capsules USP, 10 mEq, the therapeutic equivalent to the reference listed drug product, Potassium Chloride Extended-Release Capsules USP, 10 mEq, of Actavis Laboratories FL, Inc.

According to IMS Health sales data for the 12 month period ending November 2015, the Potassium Chloride Extended-Release Capsules, 10 mEq Market1 achieved annual sales of approximately $74.1 million.

Glenmark’s current portfolio consists of 105 products authorized for distribution in the US marketplace and 63 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1981.50 -11.20 (-0.56%)
29-Jan-2026 15:24 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1587.55
Dr. Reddys Lab 1207.70
Cipla 1320.60
Zydus Lifesciences 890.75
Lupin 2125.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×